An integrated approach towards the discovery of novel non-nucleoside Leishmania major pteridine reductase 1 inhibitors

Eur J Med Chem. 2017 May 26:132:322-332. doi: 10.1016/j.ejmech.2017.03.043. Epub 2017 Mar 27.

Abstract

Despite the fact that Leishmania ssp are pteridine auxotrophs, Dihydrofolate Reductase-Thymidylate Synthase (DHFR-TS) inhibitors are ineffective against Leishmania major. On the other hand Pteridine Reductase 1 (PTR1) inhibitors proved to be lethal to the parasite. Aiming at identifying hits that lie outside the chemical space of known PTR1 inhibitors, pharmacophore models that differentiate true-binders from decoys and explain the structure-activity relationships of known inhibitors were employed to virtually screen the lead-like subset of ZINC database. This approach leads to the identification of Z80393 (IC50 = 32.31 ± 1.18 μM), whose inhibition mechanism was investigated by Thermal Shift Assays. This experimental result supports a competitive mechanism and was crucial to establish the docking search space as well as select the best pose, which was then investigated by molecular dynamics studies that corroborate the hit putative binding profile towards LmPTR1. The information gathered from such studies shall be useful to design more potent non-nucleoside LmPTR1 inhibitors.

Keywords: Docking; Molecular dynamics; Pharmacophore models; Pteridine reductase 1; Thermal shift assays.

MeSH terms

  • Drug Discovery
  • Leishmania major / drug effects*
  • Leishmania major / enzymology
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Oxidoreductases / antagonists & inhibitors*
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Oxidoreductases
  • pteridine reductase